BioSpace News Archive

NeuroMetrix, Inc. reported financial and business highlights for the quarter ended June 30, 2020. The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health conditions.

-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone

The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, announced it will report its second quarter 2020 financial results on Thursday, August 6, 2020, after the market close. President and CEO Peter D. Holt and CFO Jake Singleton will hold a conference call at 5:00 p.m. ET that day to discuss the results. To gain immediate access to the call, bypass the operator and avoid the queue, you may pre

Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that it has entered into a securities purchase agreement with affiliates of an existing shareholder, RTW Investments, LP, for a $25 million private placement. The private placement is expected to close on or about July 24, 2020, subject to the satisfaction of customary closing conditions.

Longwood Fund builds on decades of creating leading biotechs with multiple approved drugs

Global life sciences leader selects Vault Study Startup and Vault eTMF to improve trial efficiency